c-Fos Expression as a Predictor in Ovarian Cancer
Author Information
Author(s): Mahner S, Baasch C, Schwarz J, Hein S, Wölber L, Jänicke F, Milde-Langosch K
Primary Institution: University Medical Center Hamburg-Eppendorf
Hypothesis
Does c-Fos expression correlate with progression and survival in ovarian carcinoma?
Conclusion
Loss of c-Fos expression is associated with poorer progression-free and overall survival in ovarian cancer patients.
Supporting Evidence
- Reduced c-Fos expression was associated with shorter progression-free survival.
- Patients with low c-Fos expression had a median overall survival of 23.8 months.
- High c-Fos expression correlated with better survival outcomes.
Takeaway
This study found that lower levels of a protein called c-Fos in ovarian cancer patients can mean they might not live as long or do as well after treatment.
Methodology
The study analyzed c-Fos expression in tumor samples from 101 patients using western blot analysis and immunohistochemistry.
Potential Biases
Potential selection bias due to non-consecutive patient sampling.
Limitations
The study is retrospective and monocentric, which may introduce selection bias.
Participant Demographics
{"mean_age":59.2,"age_range":"21-87","FIGO_stage_distribution":{"I":10,"II":8,"III":60,"IV":23}}
Statistical Information
P-Value
0.003
Confidence Interval
0.353–0.870
Statistical Significance
p=0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website